Trends in Use of and Survival after Autologous Hematopoietic Cell Transplantation in North America, 1995-2005: Significant Improvement in Survival for Lymphoma and Myeloma during a Period of Increasing Recipient Age

Philip L. McCarthy, Theresa Hahn, Anna Hassebroek, Christopher Bredeson, James Gajewski, Gregory Hale, Luis Isola, Hillard M. Lazarus, Stephanie J. Lee, Charles F. LeMaistre, Fausto Loberiza, Richard Maziarz, J. Douglas Rizzo, Steven Joffe, Susan Parsons, Navneet S. Majhail

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Autologous hematopoietic cell transplantation (auto-HCT) is performed to treat relapsed and recurrent malignant disorders and as part of initial therapy for selected malignancies. This study evaluated changes in use, techniques, and survival in a population-based cohort of 68,404 patients who underwent first auto-HCT in a US or Canadian center between 1994 and 2005 and were reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). The mean annual number of auto-HCTs performed was highest during 1996-1999 (6948), and decreased subsequently 2000-2003 (4783), owing mainly to fewer auto-HCTs done to treat breast cancer. However, the mean annual number of auto-HCTs increased from 5278 annually in 1994-1995 to 5459 annually in 2004-2005, reflecting increased use for multiple myeloma, non-Hodgkin lymphoma, and Hodgkin lymphoma. Despite an increase in the median recipient age from 44 to 53years, there has been a significant improvement in overall survival (OS) from 1994 to 2005 in patients with chemotherapy-sensitive relapsed non-Hodgkin lymphoma (day+100 OS, from 85% to 96%; 1-year OS, from 68% to 80%; P40years) and older (>60years) individuals.

Original languageEnglish (US)
Pages (from-to)1116-1123
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Volume19
Issue number7
DOIs
StatePublished - Jul 2013

Fingerprint

Cell Transplantation
North America
Lymphoma
Survival
Non-Hodgkin's Lymphoma
Multiple Myeloma
Hodgkin Disease
Bone Marrow
Breast Neoplasms
Transplants
Drug Therapy
Research
Population
Neoplasms
Therapeutics

Keywords

  • Autologous transplantation
  • Lymphoma
  • Myeloma
  • Survival
  • Treatment-related mortality

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Trends in Use of and Survival after Autologous Hematopoietic Cell Transplantation in North America, 1995-2005 : Significant Improvement in Survival for Lymphoma and Myeloma during a Period of Increasing Recipient Age. / McCarthy, Philip L.; Hahn, Theresa; Hassebroek, Anna; Bredeson, Christopher; Gajewski, James; Hale, Gregory; Isola, Luis; Lazarus, Hillard M.; Lee, Stephanie J.; LeMaistre, Charles F.; Loberiza, Fausto; Maziarz, Richard; Rizzo, J. Douglas; Joffe, Steven; Parsons, Susan; Majhail, Navneet S.

In: Biology of Blood and Marrow Transplantation, Vol. 19, No. 7, 07.2013, p. 1116-1123.

Research output: Contribution to journalArticle

McCarthy, PL, Hahn, T, Hassebroek, A, Bredeson, C, Gajewski, J, Hale, G, Isola, L, Lazarus, HM, Lee, SJ, LeMaistre, CF, Loberiza, F, Maziarz, R, Rizzo, JD, Joffe, S, Parsons, S & Majhail, NS 2013, 'Trends in Use of and Survival after Autologous Hematopoietic Cell Transplantation in North America, 1995-2005: Significant Improvement in Survival for Lymphoma and Myeloma during a Period of Increasing Recipient Age', Biology of Blood and Marrow Transplantation, vol. 19, no. 7, pp. 1116-1123. https://doi.org/10.1016/j.bbmt.2013.04.027
McCarthy, Philip L. ; Hahn, Theresa ; Hassebroek, Anna ; Bredeson, Christopher ; Gajewski, James ; Hale, Gregory ; Isola, Luis ; Lazarus, Hillard M. ; Lee, Stephanie J. ; LeMaistre, Charles F. ; Loberiza, Fausto ; Maziarz, Richard ; Rizzo, J. Douglas ; Joffe, Steven ; Parsons, Susan ; Majhail, Navneet S. / Trends in Use of and Survival after Autologous Hematopoietic Cell Transplantation in North America, 1995-2005 : Significant Improvement in Survival for Lymphoma and Myeloma during a Period of Increasing Recipient Age. In: Biology of Blood and Marrow Transplantation. 2013 ; Vol. 19, No. 7. pp. 1116-1123.
@article{ec90c6822c8248a4861645c8750c7fc7,
title = "Trends in Use of and Survival after Autologous Hematopoietic Cell Transplantation in North America, 1995-2005: Significant Improvement in Survival for Lymphoma and Myeloma during a Period of Increasing Recipient Age",
abstract = "Autologous hematopoietic cell transplantation (auto-HCT) is performed to treat relapsed and recurrent malignant disorders and as part of initial therapy for selected malignancies. This study evaluated changes in use, techniques, and survival in a population-based cohort of 68,404 patients who underwent first auto-HCT in a US or Canadian center between 1994 and 2005 and were reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). The mean annual number of auto-HCTs performed was highest during 1996-1999 (6948), and decreased subsequently 2000-2003 (4783), owing mainly to fewer auto-HCTs done to treat breast cancer. However, the mean annual number of auto-HCTs increased from 5278 annually in 1994-1995 to 5459 annually in 2004-2005, reflecting increased use for multiple myeloma, non-Hodgkin lymphoma, and Hodgkin lymphoma. Despite an increase in the median recipient age from 44 to 53years, there has been a significant improvement in overall survival (OS) from 1994 to 2005 in patients with chemotherapy-sensitive relapsed non-Hodgkin lymphoma (day+100 OS, from 85{\%} to 96{\%}; 1-year OS, from 68{\%} to 80{\%}; P40years) and older (>60years) individuals.",
keywords = "Autologous transplantation, Lymphoma, Myeloma, Survival, Treatment-related mortality",
author = "McCarthy, {Philip L.} and Theresa Hahn and Anna Hassebroek and Christopher Bredeson and James Gajewski and Gregory Hale and Luis Isola and Lazarus, {Hillard M.} and Lee, {Stephanie J.} and LeMaistre, {Charles F.} and Fausto Loberiza and Richard Maziarz and Rizzo, {J. Douglas} and Steven Joffe and Susan Parsons and Majhail, {Navneet S.}",
year = "2013",
month = "7",
doi = "10.1016/j.bbmt.2013.04.027",
language = "English (US)",
volume = "19",
pages = "1116--1123",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Trends in Use of and Survival after Autologous Hematopoietic Cell Transplantation in North America, 1995-2005

T2 - Significant Improvement in Survival for Lymphoma and Myeloma during a Period of Increasing Recipient Age

AU - McCarthy, Philip L.

AU - Hahn, Theresa

AU - Hassebroek, Anna

AU - Bredeson, Christopher

AU - Gajewski, James

AU - Hale, Gregory

AU - Isola, Luis

AU - Lazarus, Hillard M.

AU - Lee, Stephanie J.

AU - LeMaistre, Charles F.

AU - Loberiza, Fausto

AU - Maziarz, Richard

AU - Rizzo, J. Douglas

AU - Joffe, Steven

AU - Parsons, Susan

AU - Majhail, Navneet S.

PY - 2013/7

Y1 - 2013/7

N2 - Autologous hematopoietic cell transplantation (auto-HCT) is performed to treat relapsed and recurrent malignant disorders and as part of initial therapy for selected malignancies. This study evaluated changes in use, techniques, and survival in a population-based cohort of 68,404 patients who underwent first auto-HCT in a US or Canadian center between 1994 and 2005 and were reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). The mean annual number of auto-HCTs performed was highest during 1996-1999 (6948), and decreased subsequently 2000-2003 (4783), owing mainly to fewer auto-HCTs done to treat breast cancer. However, the mean annual number of auto-HCTs increased from 5278 annually in 1994-1995 to 5459 annually in 2004-2005, reflecting increased use for multiple myeloma, non-Hodgkin lymphoma, and Hodgkin lymphoma. Despite an increase in the median recipient age from 44 to 53years, there has been a significant improvement in overall survival (OS) from 1994 to 2005 in patients with chemotherapy-sensitive relapsed non-Hodgkin lymphoma (day+100 OS, from 85% to 96%; 1-year OS, from 68% to 80%; P40years) and older (>60years) individuals.

AB - Autologous hematopoietic cell transplantation (auto-HCT) is performed to treat relapsed and recurrent malignant disorders and as part of initial therapy for selected malignancies. This study evaluated changes in use, techniques, and survival in a population-based cohort of 68,404 patients who underwent first auto-HCT in a US or Canadian center between 1994 and 2005 and were reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). The mean annual number of auto-HCTs performed was highest during 1996-1999 (6948), and decreased subsequently 2000-2003 (4783), owing mainly to fewer auto-HCTs done to treat breast cancer. However, the mean annual number of auto-HCTs increased from 5278 annually in 1994-1995 to 5459 annually in 2004-2005, reflecting increased use for multiple myeloma, non-Hodgkin lymphoma, and Hodgkin lymphoma. Despite an increase in the median recipient age from 44 to 53years, there has been a significant improvement in overall survival (OS) from 1994 to 2005 in patients with chemotherapy-sensitive relapsed non-Hodgkin lymphoma (day+100 OS, from 85% to 96%; 1-year OS, from 68% to 80%; P40years) and older (>60years) individuals.

KW - Autologous transplantation

KW - Lymphoma

KW - Myeloma

KW - Survival

KW - Treatment-related mortality

UR - http://www.scopus.com/inward/record.url?scp=84879336748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879336748&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2013.04.027

DO - 10.1016/j.bbmt.2013.04.027

M3 - Article

C2 - 23660172

AN - SCOPUS:84879336748

VL - 19

SP - 1116

EP - 1123

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 7

ER -